Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Bones, Joints, Muscles and Skin›Pityriasis Rosea

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Pityriasis Rosea

Bones, Joints, Muscles and Skin · NLM MeSH · updated 2026-11-04 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A mild exanthematous inflammation of unknown etiology.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (917 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A mild exanthematous inflammation of unknown etiology. It is characterized by the presence of salmon-colored maculopapular lesions. The most striking feature is the arrangement of the lesions such that the long axis is parallel to the lines of cleavage. The eruptions are usually generalized, affecting chiefly the trunk, and the course is often self-limiting.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Where it fits in the MeSH classification

Broader topics
Pityriasis

Research landscape

PubMed indexes 469 records tagged with the MeSH heading “Pityriasis Rosea” (counts retrieved 2026-11-04). 98 of them (20.9%) were published from 2020 onward, and the busiest period so far is 2000-2009 with 137 records.

Reviews account for 61 records (13.0%) and meta-analyses for 4. Randomized controlled trials number 9 (1.9%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 97 records; 2000-2009: 137 records; 2010-2019: 137 records; 2020 onward: 98 records97through 19991372000-20091372010-2019982020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 199997
2000-2009137
2010-2019137
2020 onward98
Share of records by publication typeReviews: 13.0 percent; Meta-analyses: 0.9 percent; Randomized controlled trials: 1.9 percentReviews13.0% (61)Meta-analyses0.9% (4)Randomized controlled trials1.9% (9)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 469 PubMed records
TypeRecordsShare
Reviews6113.0%
Meta-analyses40.9%
Randomized controlled trials91.9%

Method: PubMed query "Pityriasis Rosea"[MeSH Terms] with publication-type and date filters, retrieved 2026-11-04.

Reading the evidence in bones, joints, muscles and skin

Joint, bone, muscle and skin conditions are often judged by pain scores, function questionnaires, imaging or photographs, and symptoms can fluctuate, so placebo response and natural improvement matter. Imaging changes are common in people without symptoms. Nothing on this page is advice about treatment. Check how outcomes were measured, whether the comparison group received a placebo or usual care, and how long the benefit lasted.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
The Role of Cytokines, Chemokines, and Growth Factors in the Pathogenesis of Pityriasis Rosea
Drago F, Ciccarese G, Broccolo F, Ghio M, Contini P, Thanasi H, et al.
2015Research article
Design not recorded in structured metadata
21cc by
PMID 26451078 · DOI · PMC4584227
Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: A case report
Birlutiu V, Birlutiu RM, Iancu GM
2021Research article
Design not recorded in structured metadata
10cc by
PMID 33832113 · DOI · PMC8036126
Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: A systematic review
Khan I, Elsanousi AA, Shareef AM, Tebha SS, Arif A, Gul S
2023Systematic review
Design not recorded in structured metadata
9cc by
PMID 37102660 · DOI · PMC10091373
Herald Patch as the Only Evidence of Pityriasis Rosea: Clinical, Laboratory and Pathogenetic Features
Drago F, Herzum A, Varesano S, Serviddio G, Broccolo F, Ciccarese G
2025Research article
Design not recorded in structured metadata
0cc by
PMID 39861908 · DOI · PMC11768941

The Role of Cytokines, Chemokines, and Growth Factors in the Pathogenesis of Pityriasis Rosea [1]

Research article Drago F, Ciccarese G, Broccolo F, Ghio M, Contini P, Thanasi H, et al. · · 2015 · cited 21 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
IntroductionPityriasis rosea (PR) is an exanthematous disease related to human herpesvirus- (HHV-) 6/7 reactivation.
Closing excerpt
ConclusionsOur findings suggest that these inflammatory mediators may modulate PR pathogenesis in synergistic manner.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (193 words)

IntroductionPityriasis rosea (PR) is an exanthematous disease related to human herpesvirus- (HHV-) 6/7 reactivation. The network of mediators involved in recruiting the infiltrating inflammatory cells has never been studied. Object. To investigate the levels of serum cytokines, growth factors, and chemokines in PR and healthy controls in order to elucidate the PR pathogenesis.Materials and methodsInterleukin- (IL-) 1, IL-6, IL-17, interferon- (IFN-) γ, tumor necrosis factor- (TNF-) α, vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor (G-CSF), and chemokines, CXCL8 (IL-8) and CXCL10 (IP-10), were measured simultaneously by a multiplex assay in early acute PR patients' sera and healthy controls. Subsequently, sera from PR patients were analysed at 3 different times (0, 15, and 30 days).Results and discussionSerum levels of IL-17, IFN-γ, VEGF, and IP-10 resulted to be upregulated in PR patients compared to controls. IL-17 has a key role in host defense against pathogens stimulating the release of proinflammatory cytokines/chemokines. IFN-γ has a direct antiviral activity promoting NK cells and virus specific T cells cytotoxicity. VEGF stimulates vasculogenesis and angiogenesis. IP-10 can induce chemotaxis, apoptosis, cell growth, and angiogenesis.ConclusionsOur findings suggest that these inflammatory mediators may modulate PR pathogenesis in synergistic manner.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 26451078 · DOI · PMC4584227

Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: A case report [2]

Research article Birlutiu V, Birlutiu RM, Iancu GM · · 2021 · cited 10 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
RationalePityriasis rosea Gibert is an erythematous-papulosquamous dermatosis that frequently occurs in young adults.
Closing excerpt
LessonsOur reported case adds to the other findings regarding the association of PR with SARS-CoV-2 infection, in the context of the pandemic, suggesting the need to test patients with PR skin lesions for SARS-CoV-2 infection.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (288 words)

RationalePityriasis rosea Gibert is an erythematous-papulosquamous dermatosis that frequently occurs in young adults. The etiopathogenesis of PR is still unknown, but is frequently associated with episodes of upper respiratory tract infections. It is likely that a new viral trigger of pityriasis rosea is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Patient concernsWe present the case of a female patient in whom the diagnosis of pityriasis rosea led to the investigation and diagnosis of the SARS-CoV-2 infection. The patient presented to the Department of Dermatology for a 3 week duration of an extremely pruritic erythematous-squamous lesion, initially on the trunk and upper limbs, with extension to the lower limbs in the last week and the lesion respected the cephalic extremity, palms, and soles. One week before the rash, respiratory tract infection symptomatology was observed by the patient. At home, she underwent systemic treatment with antihistamines and topical medication with dermatocorticosteroids. The evolution was unfavorable, with the spread of the lesions and the accentuation of the pruritus.DiagnosesConsidering the actual epidemiological context, we performed a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay from nasal and pharyngeal swabs for coronavirus disease 2019 (COVID-19) to investigate the PR etiology. The patient had a positive RT-PCR result, and was confirmed with SARS-CoV-2 infection.InterventionsTreatment was initiated with systemic corticosteroid therapy - hydrocortisone hemisuccinate 200 mg/day for 7 days, and loratadine 10 mg 2 times a day. Also, topical medication with dermatocorticosteroids and emollients was associated.OutcomeUnder the treatment that was initiated a partial remission of the lesions after 7 days was observed.LessonsOur reported case adds to the other findings regarding the association of PR with SARS-CoV-2 infection, in the context of the pandemic, suggesting the need to test patients with PR skin lesions for SARS-CoV-2 infection.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 33832113 · DOI · PMC8036126

Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: A systematic review [3]

Systematic review Khan I, Elsanousi AA, Shareef AM, Tebha SS, Arif A, Gul S · · 2023 · cited 9 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundAfter introducing Covid-19 vaccines, a few side effects were reported, pityriasis rosea being one of them.
Closing excerpt
ConclusionThe association between pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccines was established, but given the scarcity of studies, there is a need to conduct different clinical trials to confirm this association further and study the etiology and mechanism of the disease.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (187 words)

BackgroundAfter introducing Covid-19 vaccines, a few side effects were reported, pityriasis rosea being one of them. Therefore, this study will systematically review its manifestation afteradministration.MethodsDatabases were searched, covering a timeline from December 1, 2019 to February 28, 2022. Data were independently extracted and accessed for bias. SPSS statistical software version 25 was used for appropriate inferential statistics.ResultsThirty-one studies were included for data extraction after screening following the eligibility criteria. A total of 111 people were identified to have developed pityriasis rosea or pityriasis rosea-like eruptions after vaccination, out of which 36 (55.38%) were female. The average age of incidence was calculated to be 44.92 years, and 63 (62.37%) people presented after administration of the first dose. It was found popularly in the trunk area, either asymptomatically or with mild symptoms. Meantime the onset, was 8.58 days, and meantime it took to recover, was 6.44 weeks.ConclusionThe association between pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccines was established, but given the scarcity of studies, there is a need to conduct different clinical trials to confirm this association further and study the etiology and mechanism of the disease.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37102660 · DOI · PMC10091373

Herald Patch as the Only Evidence of Pityriasis Rosea: Clinical, Laboratory and Pathogenetic Features [4]

Research article Drago F, Herzum A, Varesano S, Serviddio G, Broccolo F, Ciccarese G · · 2025

Abstract reading summary — source excerpts
Opening excerpt
Pityriasis rosea (PR) is a self-limited exanthem associated with the endogenous systemic reactivation of human herpesvirus (HHV)-6 and HHV-7.
Closing excerpt
This rare variant of PR might be considered an abortive form of the exanthem that occurs when the HHV-6/7 reactivation from latency is contrasted by a more robust immunological response than in classic PR.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (249 words)

Pityriasis rosea (PR) is a self-limited exanthem associated with the endogenous systemic reactivation of human herpesvirus (HHV)-6 and HHV-7. The disease typically begins with a single erythematous patch on the trunk (herald patch), followed by a secondary eruption of smaller papulosquamous lesions. Rarely, the herald patch may be the only cutaneous manifestation of PR. The present work aimed to examine the clinical and laboratory features of the PR cases characterized by the herald patch as the sole cutaneous manifestation and to compare them with the classic form of PR. An observational, retrospective study was conducted on patients presenting with herald patch as the only sign of PR (cases) and on a series of age- and sex-matched patients who presented with a typical PR pattern (controls). The records of the patients were extracted from a PR registry, which collected data on patients with PR diagnosed from 2003 to 2023 by at least two dermatologists from the same study team. Nineteen patients (eleven males, eight females) with a mean age of 27.1 years presented the herald patch as the only cutaneous manifestation of PR. Nineteen age- and sex-matched patients were considered controls. In the cases, the exanthem duration was shorter than in controls, and the mean HHV-6 and HHV-7 DNA plasma load was lower than in controls. This rare variant of PR might be considered an abortive form of the exanthem that occurs when the HHV-6/7 reactivation from latency is contrasted by a more robust immunological response than in classic PR.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39861908 · DOI · PMC11768941

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology [5]
    Drago F, Broccolo F, Rebora A · J Am Acad Dermatol · 2009 · cited 98 times (Europe PMC)
  • Research article Pityriasis Rosea: A Comprehensive Classification [6]
    Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A · Dermatology · 2016 · cited 59 times (Europe PMC)
  • Research article Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature [7]
    Drago F, Ciccarese G, Javor S, Javor S, Parodi A · J Eur Acad Dermatol Venereol · 2016 · cited 43 times (Europe PMC)
  • Research article SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review [8]
    Avallone G, Quaglino P, Cavallo F, Roccuzzo G, Ribero S, Zalaudek I, et al. · Int J Dermatol · 2022 · cited 39 times (Europe PMC)
  • Research article Pityriasis rosea: an important papulosquamous disorder [9]
    González LM, Allen R, Janniger CK, Schwartz RA · Int J Dermatol · 2005 · cited 39 times (Europe PMC)
  • Research article Pityriasis rosea--an update [10]
    Chuh A, Lee A, Zawar V, Sciallis G, Kempf W · Indian J Dermatol Venereol Leprol · 2005 · cited 28 times (Europe PMC)

References

  1. Drago F, Ciccarese G, Broccolo F, Ghio M, Contini P, Thanasi H, et al.. The Role of Cytokines, Chemokines, and Growth Factors in the Pathogenesis of Pityriasis Rosea. . 2015. PMID 26451078 · DOI · PMC4584227
  2. Birlutiu V, Birlutiu RM, Iancu GM. Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: A case report. . 2021. PMID 33832113 · DOI · PMC8036126
  3. Khan I, Elsanousi AA, Shareef AM, Tebha SS, Arif A, Gul S. Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: A systematic review. . 2023. PMID 37102660 · DOI · PMC10091373
  4. Drago F, Herzum A, Varesano S, Serviddio G, Broccolo F, Ciccarese G. Herald Patch as the Only Evidence of Pityriasis Rosea: Clinical, Laboratory and Pathogenetic Features. . 2025. PMID 39861908 · DOI · PMC11768941
  5. Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol. 2009. PMID 19615540 · DOI
  6. Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A. Pityriasis Rosea: A Comprehensive Classification. Dermatology. 2016. PMID 27096928 · DOI
  7. Drago F, Ciccarese G, Javor S, Javor S, Parodi A. Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. J Eur Acad Dermatol Venereol. 2016. PMID 25545307 · DOI
  8. Avallone G, Quaglino P, Cavallo F, Roccuzzo G, Ribero S, Zalaudek I, et al.. SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review. Int J Dermatol. 2022. PMID 35141881 · DOI · PMC9111829
  9. González LM, Allen R, Janniger CK, Schwartz RA. Pityriasis rosea: an important papulosquamous disorder. Int J Dermatol. 2005. PMID 16135147 · DOI
  10. Chuh A, Lee A, Zawar V, Sciallis G, Kempf W. Pityriasis rosea--an update. Indian J Dermatol Venereol Leprol. 2005. PMID 16394453 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-11-04; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-11-04.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • PityriasisBones, Joints, Muscles and Skin
  • Pityriasis Rubra PilarisBones, Joints, Muscles and Skin
  • Pityriasis LichenoidesBones, Joints, Muscles and Skin
  • ParapsoriasisBones, Joints, Muscles and Skin
  • Psoriatic ArthritisBones, Joints, Muscles and Skin
  • Lichen PlanusBones, Joints, Muscles and Skin

All 113 articles in Bones, Joints, Muscles and Skin →

At a glance

469
PubMed records on this heading
21%
published since 2020
61
review articles
9
randomized trials
10
verified references below

Counts come from PubMed on 2026-11-04; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • PityriasisBones, Joints, Muscles and Skin
  • Pityriasis Rubra PilarisBones, Joints, Muscles and Skin
  • Pityriasis LichenoidesBones, Joints, Muscles and Skin
  • ParapsoriasisBones, Joints, Muscles and Skin
  • Psoriatic ArthritisBones, Joints, Muscles and Skin

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support